Hims & Hers stabilizes after upsized $350M convertible note, but pivot risks remain

What happened

Hims & Hers upsized its convertible note offering to $350 million, with shares trading flat pre-market as the market digested the dilution. The company's Q1 2026 results showed a net loss of $92.1 million and gross margin compression to 65% from 73% a year ago, driven by the strategic shift from compounded to branded GLP-1 drugs. The offering bolsters liquidity to $750.9 million, providing a buffer for regulatory risks including a DOJ referral and FDA scrutiny. However, management guided for further gross margin degradation and the success of the branded GLP-1 pivot is unproven beyond the initial launch. The stock's stabilization reflects reduced near-term liquidity fears, but the investment case hinges on sustainable margin recovery and resolution of legal overhangs.

Implication

Over the next 12 months, the stock's direction will be determined by Q2-Q3 2026 evidence that branded GLP-1 volumes scale with stable margins and no adverse DOJ/FDA actions. A wait-and-see approach is warranted until gross margin stabilizes above 64% and regulatory risks recede.

Thesis delta

The convertible note offering shifts focus from liquidity risk to execution risk: the company now has the capital to navigate its pivot, but the core debate moves to whether it can maintain growth and margins while transitioning to branded GLP-1 drugs. The bear case of a forced shutdown due to regulatory action is partially mitigated, but the bull case requires demonstrable proof of sustainable unit economics.